Using immune cell testing to guide cytomegalovirus prevention after lung transplant
Follows immune response to cytomegalovirus in adults who received a lung transplant.
Key facts
- Who runs it
- University of Miami
- Where
- Miami, United StatesSee the site
- Trial code
- Registry title
- Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients
- Status
- Recruiting
- People taking part
- 100 people, planned
- Started
- 3 Jul 2024
- Expected to end
- 30 Dec 2026
- Type of study
- Observational
- Record updated
- 23 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults waiting for a lung transplant who have had past CMV infection, shown by a blood test. The trial follows their immune response to CMV (cytomegalovirus) for 1 year.
- Age
- 18 Years to 75 Years
- Sex
- All sexes can join.
- Disease stage
- People expected to receive a lung transplant, either double lung or single lung.
- Biomarker or test result
- Positive CMV IgG blood test before the transplant (a sign of past CMV infection).
Main reasons for not taking part
- Negative CMV IgG before the transplant
- Pregnant or breastfeeding women
- People with HIV infection
- People waiting for a combined organ transplant, such as lung-heart or lung-kidney
This trial only enrols participants who have had an organ transplant. The registry sentence this rests on: Anticipated to receive a lung transplant (both double lung and single lung)
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Adult patients over 18 years of age
- Lung transplant candidates with positive CMV IgG
- Anticipated to receive a lung transplant (both double lung and single lung)
Who cannot take part
- Negative CMV IgG prior transplant
- HIV infected patients
- Combined organ (e.g., lung-heart, lung-kidney) transplant candidates
- Pregnant or breastfeeding women
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Where in United States
- University of MiamiMiami, United StatesContact: Yoichiro Natori, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.
The group in the trial
- Prophylaxis guided by Cytomegalovirus-specific T cell Immunity
The immunological response of participants in this group will be followed for 1 year.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients: a Single Center Prospective Study
- Plain-language title
- Using immune cell testing to guide cytomegalovirus prevention after lung transplantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06494033, who can take part
- Record updated
- 23 March 2026